Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, gives an overview of which clinical trials to watch in the chronic lymphocytic leukemia space.
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, gives an overview of which clinical trials to watch in the chronic lymphocytic leukemia space (CLL).
For more on CLL, watch our Peer Exchanges video series on patient accessibility of oral oncolytics.
Some of the major trials were the Alliance trial that was presented at the ASH meeting. That was the main trial that established ibrutinib as the gold standard, category 1 recommendation for first-line therapy for patients. Some of the other trials to look out for are the CAPTIVATE trial, looking at ibrutinib and venetoclax in the frontline setting. The iLLUMINATE trial, studying ibrutinib in combination with obinutuzumab, that did lead recently to the FDA approval for that combination. I think that data is still early, maturing. Some of our other long-term follow-up studies, from some of the landmark trials such as the RESONATE trial with ibrutinib in the first-line and relapsed/refractory setting, learning more about the sustainability and the long-term response to therapy which is very positive. As well as with the MURANO trial data with venetoclax, looking at potentially being able to stop therapy because of MRD achievement in those patients. So, those are some of the trials to look for. There’s definitely a number, again, in the frontline setting as well as relapsed/refractory using these small molecule inhibitors in combination especially with immunotherapy. As well as potentially for those patients with a specific mutation called the IgVH mutation, really trying to understand the role of chemoimmunotherapy because it seems like those patients with those mutations still do benefit best from a chemoimmunotherapy approach as opposed to the small molecule inhibitor like ibrutinib for example.